Iovance Biotherapeutics (HAM:2LB) Other Operating Expense: €23.2 Mil (TTM As of Mar. 2026)


HAM:2LB Iovance Biotherapeutics Inc HAM:2LB
44 GF Score
Price €3.78
GF Value €17.09
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Iovance Biotherapeutics Other Operating Expense?

Iovance Biotherapeutics HAM:2LB +2.44% 44 Other Operating Expense is €23.2 Mil as of Mar. 2026. GuruFocus rates HAM:2LB with a GF Score™ of 44/100 and a GF Value™ of €17.09 (Possible Value Trap). The stock has 2 warning signs investors should review.

Iovance Biotherapeutics's Other Operating Expense for the three months ended in Mar. 2026 was €7.4 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €23.2 Mil.

Iovance Biotherapeutics's quarterly Other Operating Expense increased from Sep. 2025 (€7.7 Mil) to Dec. 2025 (€8.1 Mil) but then declined from Dec. 2025 (€8.1 Mil) to Mar. 2026 (€7.4 Mil).

Iovance Biotherapeutics's annual Other Operating Expense increased from Dec. 2023 (€19.6 Mil) to Dec. 2024 (€35.9 Mil) but then declined from Dec. 2024 (€35.9 Mil) to Dec. 2025 (€30.7 Mil).

Iovance Biotherapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Iovance Biotherapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iovance Biotherapeutics Other Operating Expense Chart

Iovance Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 -0.00 19.65 35.91 30.69

Iovance Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.46 -0.00 7.67 8.13 7.39
HAM:2LB
44GF Score
Iovance Biotherapeutics Inc HAM:2LB
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Iovance Biotherapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €23.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of €23.2 Mil mean?
Iovance Biotherapeutics (HAM:2LB) has a Other Operating Expense of €23.2 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Iovance Biotherapeutics and its competitors.
Is Iovance Biotherapeutics' Other Operating Expense too high?
Iovance Biotherapeutics' current Other Operating Expense is €23.2 Mil. Overall, Iovance Biotherapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' Other Operating Expense compare to SNDX and GLUE?
Iovance Biotherapeutics' Other Operating Expense of €23.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Iovance Biotherapeutics and its competitors. Iovance Biotherapeutics's current Other Operating Expense is €23.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (HAM:2LB) is currently considered Possible Value Trap. The stock's GF Value™ is €17.09, compared to a current price of €3.78 — trading 77.9% below its estimated fair value. The current Other Operating Expense is €23.2 Mil. Iovance Biotherapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Iovance Biotherapeutics (HAM:2LB), the current Other Operating Expense is €23.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Iovance Biotherapeutics (HAM:2LB) Overvalued in 2026?

Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued. The current stock price of €3.78 is trading 77.9% below its estimated GF Value™ of €17.09. GuruFocus considers Iovance Biotherapeutics to be Possible Value Trap.

Key valuation signals for HAM:2LB:

  • Other Operating Expense: €23.2 Mil
  • GF Value™: €17.09 vs. price of €3.78 (77.9% below fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the HAM:2LB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Iovance Biotherapeutics Business Description

Address 825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
44GF Score

Get the complete analysis for HAM:2LB

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.78
Price
€17.09
GF Value